MedTrace Logo

Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy

NCT05142501 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2022-09-15

No results posted yet for this study

Summary

Observation of humoral and cellular immune response after additional dose vaccine with different COVID-19 vaccines in ESKD patients in hemodialysis therapy.

Conditions

  • Chronic Kidney Diseases
  • COVID-19
  • Hemodialysis

Interventions

OTHER

Blood samples

Four consecutive blood sampling throughout the overall follow-up period of 12 months.

Sponsors & Collaborators

  • Fresenius Medical Care Deutschland GmbH

    lead INDUSTRY

Principal Investigators

  • Pedro Ponce, Dr · Nephrocare Portugal

  • Maria Eva Baró Salvador, Dr · Fresenius Medical Care España, S.A.U.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-25
Primary Completion
2022-09-02
Completion
2022-09-02

Countries

  • Portugal
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05142501 on ClinicalTrials.gov